Chan Henry Lee Sells 871 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 871 shares of BeOne Medicines stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $270.42, for a total value of $235,535.82. Following the completion of the transaction, the senior vice president directly owned 160 shares in the company, valued at $43,267.20. This represents a 84.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total value of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total value of $103,447.88.

BeOne Medicines Stock Down 1.7%

NASDAQ ONC traded down $4.56 during trading on Wednesday, reaching $263.61. 291,079 shares of the company’s stock were exchanged, compared to its average volume of 255,249. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22. The company’s fifty day simple moving average is $301.03 and its 200-day simple moving average is $315.60. The firm has a market capitalization of $28.92 billion, a PE ratio of 58.97 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The company had revenue of $1.51 billion for the quarter. Sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Hedge Funds Weigh In On BeOne Medicines

Several large investors have recently added to or reduced their stakes in ONC. Capital International Investors lifted its position in BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after purchasing an additional 67,808 shares during the period. Siren L.L.C. grew its holdings in shares of BeOne Medicines by 1.4% during the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after purchasing an additional 7,010 shares during the last quarter. Morgan Stanley grew its stake in shares of BeOne Medicines by 23.9% during the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock valued at $132,966,000 after purchasing an additional 84,367 shares during the last quarter. Bank of America Corp DE boosted its position in BeOne Medicines by 7.0% in the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after buying an additional 26,441 shares during the last quarter. Finally, Candriam S.C.A. boosted its stake in shares of BeOne Medicines by 31.7% in the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after purchasing an additional 62,470 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

ONC has been the subject of several research reports. Wolfe Research initiated coverage on BeOne Medicines in a report on Friday, March 27th. They set an “outperform” rating and a $340.00 price target for the company. Leerink Partners lifted their price target on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Royal Bank Of Canada lifted their price target on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Truist Financial reiterated a “buy” rating and set a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Finally, Wells Fargo & Company initiated coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.